EyePoint, Inc. (EYPT)
EYPT moved a median of -0.25% 30 minutes after news, and -0.88% by the close. How EYPT actually reacts to news — the realized, point-in-time move the market made, measured across 439 labeled events over the last three years with zero look-ahead.
EYPT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.05% | 47% | 433 |
| 30-min | -0.25% | 46% | 434 |
| 60-min | -0.52% | 42% | 434 |
| to close | -0.88% | 45% | 428 |
| Middle 50% of EYPT reactions | -2.08% to +1.40% |
|---|---|
| Median reaction (30-min) | -0.25% |
| Measured reactions | 439 |
Half of all EyePoint, Inc. news events land between -2.08% and +1.40% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How EYPT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 17 | +6.70% | 77% | +15.64% |
| Coverage initiations | 26 | -1.04% | 39% | +0.31% |
| Rating reiterations | 62 | +0.66% | 66% | +0.23% |
| Price-target raises | 11 | -0.35% | 36% | -1.67% |
| Price-target cuts | 15 | +0.51% | 67% | +1.96% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how EYPT ranks against every other measured name →
That’s how EYPT usually reacts — get an email when it moves on news →Email me when EYPT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to EYPT's baseline. Nothing else.
Recent EYPT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against EyePoint, Inc. (EYPT) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.30% | +1.33% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against EyePoint, Inc. (EYPT) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.15% | -0.75% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages EyePoint, Inc. (EYPT) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.26% | -1.48% | |
| EyePoint, Inc. (EYPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.53% | -1.98% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages EyePoint, Inc. (EYPT) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | +3.88% | |
| EyePoint, Inc. (EYPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.27% | +6.83% | |
| EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.14% | -5.74% | |
| EyePoint, Inc. (EYPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.85% | -1.85% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against EyePoint, Inc. (EYPT) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.11% | -3.81% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages EyePoint, Inc. (EYPT) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.35% | -0.93% | |
| Form 8-K EyePoint, Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.23% | -1.62% | |
| EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting | Press release | GlobeNewswire | +4.36% | +9.86% | |
| EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | +0.11% | +0.45% | |
| EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD | Press release | GlobeNewswire | +14.97% | +21.75% | |
| Form 8-K EyePoint, Inc. For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | +14.97% | +21.75% | |
| EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +14.97% | +21.75% | |
| EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments | Press release | GlobeNewswire | +0.71% | +3.11% | |
| Form 10-Q EyePoint, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.94% | +4.74% | |
| Form 8-K EyePoint, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.71% | +3.11% | |
| Form S-8 EyePoint, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.94% | +4.74% | |
| EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME) | Press release | GlobeNewswire | -1.64% | +5.67% | |
| Form 8-K EyePoint, Inc. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -1.64% | +5.67% | |
| Form 8-K EyePoint, Inc. For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | +3.20% | -4.60% | |
| EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.19% | -7.78% | |
| EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer | Press release | GlobeNewswire | -1.76% | -1.18% | |
| Form 8-K EyePoint, Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +1.21% | +0.81% | |
| EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.49% | +6.62% | |
| EyePoint Announces Participation at Upcoming Investor Conferences | Press release | GlobeNewswire | -2.14% | +1.20% | |
| EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.05% | -5.26% | |
| EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data | Press release | GlobeNewswire | +0.19% | -1.05% | |
| Form 8-K EyePoint, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.19% | -1.05% | |
| Form 10-Q EyePoint, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.31% | +2.32% | |
| EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments | Press release | GlobeNewswire | -0.80% | -2.77% | |
| Form 8-K EyePoint, Inc. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -0.80% | -2.77% | |
| EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 | Press release | GlobeNewswire | -0.23% | -2.80% | |
| Form DEF 14A EyePoint, Inc. For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +2.31% | +0.22% | |
| Form DEFA14A EyePoint, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +2.31% | +0.22% | |
| EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.80% | -0.47% | |
| Form 8-K EyePoint, Inc. For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | +1.31% | -1.24% | |
| Form 8-K EyePoint, Inc. For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | +0.11% | -4.25% | |
| EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.07% | +0.60% | |
| Form 10-K EyePoint, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.13% | +3.96% | |
| EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments | Press release | GlobeNewswire | +0.55% | -0.83% | |
| Form 8-K EyePoint, Inc. For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +0.55% | -0.83% | |
| EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema | Press release | GlobeNewswire | +2.10% | +6.75% | |
| Form 8-K EyePoint, Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +2.10% | +6.75% | |
| EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 | Press release | GlobeNewswire | +0.93% | +3.26% | |
| EyePoint Announces Participation at Upcoming Investor Conferences | Press release | GlobeNewswire | +1.72% | -0.53% | |
| EyePoint Appoints Michael Campbell as Chief Commercial Officer | Press release | GlobeNewswire | +0.88% | -2.78% | |
| EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +10.48% | +20.24% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the EYPT section they belong to.
Where else EYPT is measured.
EYPT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Catalyst Pharmaceuticals, Inc. (CPRX) | 441 | 0.00% | 50% |
| Pacific Biosciences of California, Inc. (PACB) | 440 | -0.29% | 44% |
| Abeona Therapeutics Inc. (ABEO) | 438 | +0.09% | 51% |
| KalVista Pharmaceuticals, Inc. (KALV) | 438 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is EyePoint, Inc.'s median reaction calculated?
Every labeled EYPT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 439 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of EYPT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does EYPT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.